Brendon Stiles My friend Brendon Stiles, you are focusing on the mouse data but not RCTs...

In humans, SABR decreases progression, sometimes increases OS. Even the one negative trial (BR-002) had a HR <1.

BTW still some space in the table any positive surgical trials 😉

Important findings in this paper - patients in MA plans often have limited access to specialists, even in high population/urban settings.

A shame to see patients covered by Medicare again having access issues due to restrictive MA plans, especially for time sensitive conditions

AUA giving strong platform for all of this without a single RCT showing benefit:

auanews.net/issues/article…

We had a discussion yesterday on the value of local RT in high volume PCa based on the PFS gains seen in STAMPEDE and PEACE1 and many argued not to do so, but I do not get that point if you take into account the low cost and benefits in comparison with the drugs Alberto Bossi

Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy jnm.snmjournals.org/content/early/…

Three leading drugmakers have spent about $8 billion in the past six months to purchase companies developing radiopharmaceuticals to fight cancer bloomberg.com/news/articles/…

Super excited to activate our US version and have our site initiation visit in 2 days!

Time to show the USA can still do trials…as the UK is kicking our butt. If you can’t beat them…join them!

Valuable trial we are incredibly proud to lead RadOncUH for 🇺🇸 and to collaborate with STAMPEDE team Nick James Chris Parker and many more.

Thank you to Peter Choyke Adam Sowalsky and NIH for funding this important trial. NIHDirector

Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr gives a great overview on liquid biopsy & precision medicine status’s & future prospects in GU cancers #Cleveland precision med summit
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Cleveland Clinic MD Albert Jang, MD JAGarciaMD

So proud that Louise Emmet is a part of our panel Advanced Prostate Cancer Consensus Conference ! Register now apccc.org to be part of the discussions!

Super valuable. Otherwise you will end up shifting to doing focal therapy as RP outcomes suboptimal. Surgery is without question a skill with highly variable outcomes. Volume alone insufficient. Mastery of the art needed.

I should know as a top rated prostatectomist by various

Close now.

Giving a talk today at SAR 2024 Annual Meeting on 'Evaluation of PI-RADS 3 lesions: Review of Management and Challenges'. Thanks for the great interest in pre-session signups! #SAR24 - via #Whova event app

WE ARE GETTING READY FOR #APCCC24 🇨🇭

Still Time to Register for this HYBRID meeting onlineevent.ch/APCCC/2024
#APCCC14 Online is FREE to Certain LMIC's For those who cant make it Join

OncoAlert & Advanced Prostate Cancer Consensus Conference

Ambassadors Bringing you the TOP conversations in #ProstateCancer …

Multiple ongoing institutional and collaborative experiences demonstrating critical role of pre- and post- CAR T radiation, with significant increase in response rates, low toxicity and possibility of using technology to deliver comprehensive RT to sites of PET-avid disease.

Shankar Siva The Lancet Oncology Targeting Cancer Matthew Katz, MD 🟦 Lucinda Burke Julie McCrossin AM (She/Her) Lucinda Morris RANZCR Rad Oncology Pablo Munoz Schuffenegger Hernan Letelier Claudia Carvajal Sociedad Chilena de Radioterapia Oncológica Drew Moghanaki 🐕 Drugs are the primary driver of cost in oncology:
twitter.com/NicholasZaorsk…